Idea ID: inv006-biomarker-ykl40
Target: YKL-40 (Chitinase 3-like 1, CHI3L1)
Indication: Alzheimer's Disease, Parkinson's Disease
Approach: Monoclonal antibody against YKL-40 to reduce chronic neuroinflammation
Rationale: Elevated YKL-40 in CSF and plasma correlates with disease progression and predicts cognitive decline
YKL-40 is a chitinase-like protein produced by astrocytes, microglia, and neurons in response to inflammation:
| Study | Finding | Citation |
|---|---|---|
| CSF YKL-40 in AD | Elevated 2x in AD vs controls, correlates with tau | Craig-Schapiro et al., 2011 |
| Plasma YKL-40 | Predicts cognitive decline in MCI | Kester et al., 2019 |
| YKL-40 in PD | Elevated in PD CSF, correlates with severity | Imamura et al., 2006 |
| Longitudinal | YKL-40 predicts progression from MCI to AD | Janelidze et al., 2018 |
YKL-40 drives a pro-inflammatory cascade that accelerates neurodegeneration. Blocking YKL-40 will:
| Approach | Company | Stage |
|---|---|---|
| Anti-YKL-40 mAb | This approach | Preclinical |
| TREM2 agonists | Various | Phase 1/2 |
| Anti-IL-6R | Tocilizumab | Repurposed |
| NLRP3 inhibitors | Various | Phase 1 |
If successful, YKL-40-targeted therapy could slow disease progression by 20-30% based on biomarker modeling.